For the first time since 2003, the US Food and Drug Administration (FDA) approved the drug developed by Massachusetts-based biotechnology company Biogen for use in the treatment of Alzheimer’s.
According to the written statement from the FDA, the Alzheimer’s drug “aducanumab”, which is in the experimental stage and developed by Biogen, has been approved for use in the early stages.
The drug slows the progression of mild cognitive impairments that appear in the early stages of Alzheimer’s. Experts emphasize that the purpose of the drug is to slow the progression of the disease rather than relieving the symptoms.
SCIENTISTS SAID “NO SUFFICIENT EVIDENCE”
Thus, the FDA approved the use of an Alzheimer’s drug for the first time since 2003. On the other hand, the aforementioned approval brought with it discussions in the scientific world.
Scientists examining Biogen’s application for approval for use prepared a report last year stating that there was not enough evidence to show that this drug was effective in treatment.